341 related articles for article (PubMed ID: 23604636)
1. Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs.
Shu Y; Haque F; Shu D; Li W; Zhu Z; Kotb M; Lyubchenko Y; Guo P
RNA; 2013 Jun; 19(6):767-77. PubMed ID: 23604636
[TBL] [Abstract][Full Text] [Related]
2. Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.
Shu Y; Shu D; Haque F; Guo P
Nat Protoc; 2013 Sep; 8(9):1635-59. PubMed ID: 23928498
[TBL] [Abstract][Full Text] [Related]
3. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.
Guo P
J Nanosci Nanotechnol; 2005 Dec; 5(12):1964-82. PubMed ID: 16430131
[TBL] [Abstract][Full Text] [Related]
4. Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.
Haque F; Xu C; Jasinski DL; Li H; Guo P
Methods Mol Biol; 2017; 1632():359-380. PubMed ID: 28730451
[TBL] [Abstract][Full Text] [Related]
5. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.
Xu C; Haque F; Jasinski DL; Binzel DW; Shu D; Guo P
Cancer Lett; 2018 Feb; 414():57-70. PubMed ID: 28987384
[TBL] [Abstract][Full Text] [Related]
6. Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.
Lee TJ; Haque F; Vieweger M; Yoo JY; Kaur B; Guo P; Croce CM
Methods Mol Biol; 2015; 1297():137-52. PubMed ID: 25896001
[TBL] [Abstract][Full Text] [Related]
7. Stable RNA nanoparticles as potential new generation drugs for cancer therapy.
Shu Y; Pi F; Sharma A; Rajabi M; Haque F; Shu D; Leggas M; Evers BM; Guo P
Adv Drug Deliv Rev; 2014 Feb; 66():74-89. PubMed ID: 24270010
[TBL] [Abstract][Full Text] [Related]
8. Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA.
Cui D; Zhang C; Liu B; Shu Y; Du T; Shu D; Wang K; Dai F; Liu Y; Li C; Pan F; Yang Y; Ni J; Li H; Brand-Saberi B; Guo P
Sci Rep; 2015 Jul; 5():10726. PubMed ID: 26137913
[TBL] [Abstract][Full Text] [Related]
9. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
10. Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.
Binzel DW; Shu Y; Li H; Sun M; Zhang Q; Shu D; Guo B; Guo P
Mol Ther; 2016 Aug; 24(7):1267-77. PubMed ID: 27125502
[TBL] [Abstract][Full Text] [Related]
11. Using RNA nanoparticles with thermostable motifs and fluorogenic modules for real-time detection of RNA folding and turnover in prokaryotic and eukaryotic cells.
Zhang H; Pi F; Shu D; Vieweger M; Guo P
Methods Mol Biol; 2015; 1297():95-111. PubMed ID: 25895998
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells.
Guo P; Shu Y; Binzel D; Cinier M
Methods Mol Biol; 2012; 928():197-219. PubMed ID: 22956144
[TBL] [Abstract][Full Text] [Related]
13. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.
Shu Y; Cinier M; Shu D; Guo P
Methods; 2011 Jun; 54(2):204-14. PubMed ID: 21320601
[TBL] [Abstract][Full Text] [Related]
14. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers.
Haque F; Shu D; Shu Y; Shlyakhtenko LS; Rychahou PG; Evers BM; Guo P
Nano Today; 2012 Aug; 7(4):245-257. PubMed ID: 23024702
[TBL] [Abstract][Full Text] [Related]
15. Programmable folding of fusion RNA in vivo and in vitro driven by pRNA 3WJ motif of phi29 DNA packaging motor.
Shu D; Khisamutdinov EF; Zhang L; Guo P
Nucleic Acids Res; 2014 Jan; 42(2):e10. PubMed ID: 24084081
[TBL] [Abstract][Full Text] [Related]
16. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology.
Khaled A; Guo S; Li F; Guo P
Nano Lett; 2005 Sep; 5(9):1797-808. PubMed ID: 16159227
[TBL] [Abstract][Full Text] [Related]
17. Methods and assays for specific targeting and delivery of RNA nanoparticles to cancer metastases.
Rychahou P; Shu Y; Haque F; Hu J; Guo P; Evers BM
Methods Mol Biol; 2015; 1297():121-35. PubMed ID: 25896000
[TBL] [Abstract][Full Text] [Related]
18. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery.
Abdelmawla S; Guo S; Zhang L; Pulukuri SM; Patankar P; Conley P; Trebley J; Guo P; Li QX
Mol Ther; 2011 Jul; 19(7):1312-22. PubMed ID: 21468004
[TBL] [Abstract][Full Text] [Related]
20. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.
Guo S; Tschammer N; Mohammed S; Guo P
Hum Gene Ther; 2005 Sep; 16(9):1097-109. PubMed ID: 16149908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
